Interferon alpha-2a biosimilar - Biosidus

Drug Profile

Interferon alpha-2a biosimilar - Biosidus

Alternative Names: Biosidus interferon alpha 2a; Inferon; Inmutag; Inter 2A

Latest Information Update: 20 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biosidus S.A.
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alfa 2a stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer; Hepatitis B; Hepatitis C; Kaposi's sarcoma

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 15 Nov 2011 Launched for Cancer in Argentina (Parenteral)
  • 15 Nov 2011 Launched for Cancer in Russia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top